A strategy to design protein-based antagonists against type I cytokine receptors

by Timo Ullrich, Olga Klimenkova, Christoph Pollmann, Asma Lasram, Valeriia Hatskovska, Kateryna Maksymenko, Matej Milijaš-Jotić, Lukas Schenk, Claudia Lengerke, Marcus D. Hartmann, Jacob Piehler, Julia Skokowa, Mohammad ElGamacy

Excessive cytokine signaling resulting from dysregulation of a cytokine or its receptor can be a main driver of cancer, autoimmune, or hematopoietic disorders. Here, we leverage protein design to create tailored cytokine receptor blockers with idealized properties. Specifically, we aimed to tackle the granulocyte-colony stimulating factor receptor (G-CSFR), a mediator of different types of leukemia and autoinflammatory diseases. By modifying designed G-CSFR binders, we engineered hyper-stable proteins that function as nanomolar signaling antagonists. X-ray crystallography showed atomic-level agreement with the experimental structure of an exemplary design. Furthermore, the most potent design blocks G-CSFR in acute myeloid leukemia cells and primary human hematopoietic stem cells. Thus, the resulting designs can be used for inhibiting or homing to G-CSFR-expressing cells. Our results also demonstrate that similarly designed cytokine mimics can be used to derive antagonists to tackle other type I cytokine receptors.